Monte Carlo dose verification of VMAT treatment plans using Elekta Agility 160-leaf MLC.

In this study, we verified volumetric modulated arc therapy (VMAT) plans in an Elekta Synergy system with an integrated Agility 160-leaf multileaf collimator (MLC) by comparing them with Monte Carlo (MC)-calculated dose distributions using the AAPM TG-119 structure sets. The head configuration of the linear accelerator with the integrated MLC was simulated with the EGSnrc/BEAMnrc code. Firstly, the dosimetric properties of the MLC were evaluated with the MC technique and film measurements. Next, VMAT plans were created with the Pinnacle3 treatment planning system (TPS) for four regions in the AAPM TG-119 structures. They were then verified by comparing them with MC-calculated dose distributions using dose volume histograms (DVHs) and three-dimensional (3D) gamma analysis. The MC simulations for the Agility MLC dosimetric properties were in acceptable agreement with measurements. TPS-VMAT plans using TG-119 structure sets agreed with MC dose distributions within 2% in the comparison of D95 in planning target volumes (PTVs) evaluated from DVHs. In contrast, higher dose regions such as D20 , D10 , and D5 in PTVs for TPS tended to be smaller than MC values. This tendency was particularly noticeable for mock head and neck with complicated structures. In 3D gamma analysis, the passing rates with 3%/3mm criteria in PTVs were ≥99%, except for mock head and neck (89.5%). All passing rates for organs at risk (OARs) were in acceptable agreement of >96%. It is useful to verify dose distributions of PTVs and OARs in TPS-VMAT plans by using MC dose calculations and 3D gamma analysis.